|Bid||55.01 x 800|
|Ask||55.50 x 1200|
|Day's Range||55.00 - 56.30|
|52 Week Range||30.15 - 59.95|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.54|
SOUTH SAN FRANCISCO, Calif., April 03, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2019, the compensation committee of GBT’s.
SOUTH SAN FRANCISCO, Calif., April 02, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can make much more than 100% if theRead More...
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
SOUTH SAN FRANCISCO, Calif., March 04, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 39th Annual.
The startup is tapping a wealth of genetic information in databases and a new wave of technology in its quest to figure out why some people with a genetic mutation can have a more-severe form of a disease than others with the same mutation.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the fourth.
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 8th Annual SVB Leerink Global.
—The Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) Supports Novel Projects Aimed at Improving Access to High-Quality Healthcare for People with Sickle.
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced that data from its Phase 1/2 study of voxelotor in patients with sickle cell disease (SCD) were published online in Blood, a peer-reviewed publication of the American Society of Hematology. GBT intends to submit a New Drug Application (NDA) for voxelotor under an accelerated approval pathway to the U.S. Food and Drug Administration (FDA) later this year.
Citigroup has downgraded the gene-editing pioneer to "sell," but Wall Street has been known to make mistakes.
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 37th Annual J.P. Morgan Healthcare.
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced the appointment of Dawn Svoronos to the company’s board of directors. Ms. Svoronos has more than 30 years of experience in the biopharmaceutical industry in the United States, Canada, Europe and Asia, including a nearly 25-year tenure at Merck & Co. “Dawn is a global biopharmaceutical leader whose addition to the board will strengthen the existing breadth of talent,” said Ted W. Love, M.D., president and chief executive officer of GBT.
David Kim’s Ghost Tree Capital is a health-care oriented hedge fund with a headquarter in New York. It was founded five years ago, back in 2013, by Ken Greenberg, Matt Diaz (Trader), Brian Kim (Senior Analysts), and of course David Kim. This large advisory firm provides portfolio management services for pooled investment vehicles and pension funds. David […]
The company reported boring third-quarter 2018 operating results, but followed up with important clinical updates in the first week of December.
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Global Blood Therapeutics , Inc. (GBT), a clinical-stage biopharmaceutical company. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. GBT plans to request a pre-NDA meeting for the first quarter of 2019 and intends to provide further details regarding its plans and timing for an NDA submission as well as additional specifics on the TCD confirmatory study following this meeting.
Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $150.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT. In addition, GBT has granted the underwriters a 30-day option to purchase $22.5 million of additional shares of common stock. Cantor Fitzgerald & Co. is the sole book-running manager for the offering.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...
Black Friday is past. So is Cyber Monday. But it's not too late to buy one of the best Christmas gifts of all -- biotech stocks. Analysts think there are three biotech stocks, in particular, that look like good picks right now: Stemline Therapeutics (STML), Global Blood Therapeutics (GBT), and Sesen Bio (SESN). Let's take a closer look.Stemline: Analysts See 200% Gains Ahead of Upcoming FDA DecisionStemline filed a biologics license application (BLA) for its lead drug candidate, ELZONRIS (SL-401), which in October 2017 reported promising phase 2 data as a first-line treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN). The application has received priority review from the FDA and has a PDUFA date scheduled for February 21, 2019, which is when regulators will decide the drug's commercial fate. ELZONRIS has also been granted Breakthrough Therapy Designation and Orphan Drug Designation by the FDA."Given the strength of the pivotal study data combined with the significant unmet clinical need for BPDCN patients, we believe there is a strong likelihood of approval by the PDUFA date," Ladenburg analyst Matthew Kaplan opined. "We believe SL-401 could generate >$130 million U.S. revenues in the BPDCN indication at peak. We are encouraged by the progress of STML’s commercial preparations and look forward to updates as we move closer to the PDUFA date."Kaplan rates STML shares a Buy with a price target of $41, which implies a potential upside of nearly 300% from current levels.Wedbush's top analyst David Nierengarten added, "With stock trading near the lower end of its YTD range we would recommend investors accumulate shares going into what is likely to be a straightforward approval process for SL-401. With Breakthrough Status and BLA submitted we believe -401 is poised to be approved in early 2019, and we have confidence that STML can make a successful transition into a commercial company given small size of BPDCN market. With an EV of just about $400M, which is also what we approximate peak SL-401 sales at, we see STML as an attractive and easily digestible takeover target." (To watch Nierengarten's track record, click here)Bottom line: When it comes to Wall Street’s bet, the odds are on this biotech stock, with TipRanks analytics showcasing STML as a Strong Buy. With an average price target of $30.80, analysts are predicting massive upside potential of about 200% for the stock. In total, Stemline stock has received 6 'buy' ratings in the last three months.Global Blood: Clear Shot at Accelerated ApprovalMonday, Global Blood provided positive regulatory update on potential accelerated approval for Voxelotor in sickle cell disease (SCD) after consulting with the FDA. The company plans to have a pre-NDA FDA meeting in Q1:19 and possibly start submitting regulatory filings with a NDA in H2 2019.In reaction, Wedbush analyst Liana Moussatos boosted her price target on GBT stock to $93 (from $73), while reiterating an Outperform rating.Moussatos commented, "We remain comfortable with our August 2020 U.S. launch timing, $40.1 million 2020 sales estimate and achieving more than $1 billion in 2023. Although GBT stock greatly appreciated on December 3rd with this news, it should not be a surprise after positive comments from key opinion leaders (KOLs) participating in the FDA-ASH SCD Clinical Endpoints Workshop (October 17-18, 2018; Rockville, MD) were supportive of elevated hemoglobin in SCD (to treat hemolysis) as a primary endpoint for accelerated approval. Due to anticipated reduced regulatory and clinical risk and positive expanded HOPE Part A and HOPE-KIDS 1 results presented at ASH, we are increasing our multiple to 7x for positive Phase 3 results and raising our PT to $93 from $73. With GBT closing at $46.62 on December 3 after the news was released, we consider the stock to be undervalued in front of potentially major regulatory catalysts in 2019-2020. The Company ended Q3 with about $482.1 million in cash and we project runway into 2021 or longer depending on potential sales."Moussatos is not the only fan of the biotech company on Wall Street, as TipRanks analytics exhibit GBT as a Strong Buy. Based on 11 analysts polled in the last 3 months, 10 rate a Buy rating on Global Blood stock while only 1 recommends Hold. The 12-month average price target stands at $90.78, marking a 95% upside from where the stock is currently trading.Sesen: All Eyes on 6-Month Data Readout from VISTASesen is on-track to report updated six-month results from the ongoing Phase 3 VISTA study of Vicinium for the treatment of NMIBC in December. Recall, VISTA is a 134-patient, single-arm study with co-primary endpoints of complete response rate at 12 months and duration of response (DOR), and secondary endpoints of event-free survival, progression-free survival, overall survival, and time to cystectomy. The company previously published the initial 3-month readout back in May (39% CR rate), which was robust and within expectations.H.C. Wainwright's Swayampakula Ramakanth has weighed in with his two cents: "Based on the dinner discussions [with KOL], we believe that depending on the final VISTA results, Vicinium could have a compelling case for FDA approval. The more important factors in Vicinium’s favor are the current high unmet need for BCGunresponsive NMIBC and the drug’s excellent safety profile; with virtually no bladder-saving therapies available, a safe, proven treatment like Vicinium could enjoy a first-mover advantage with both the agency and with clinicians. In our view, Vicinium would very likely be approved should the drug achieve a 12-month complete response rate of >20% in VISTA, and should not be ruled out either if it only manages to repeat the previous 16% response rate achieved in Phase 2. Therefore, with regards to the upcoming six-month results, we believe that a response rate of >30% would be a strong positive for Sesen, while a rate on par with the 27% achieved in Phase 2 would still be on track for positive 12-month results."Ramakanth rates SESN stock a Buy with 12-month price target of $3.00, which implies a potential upside of nearly 87% upside from current levels.We can see from TipRanks that SESN has received 4 'buy ratings' in the past 12 months. Based on these ratings, the average $5.00 price target on the stock translates into upside of over 200% from the current share price. (See SESN's price targets and analyst ratings on TipRanks) More recent articles from Smarter Analyst: * Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst * Global Blood Therapeutics (GBT) Gets Attention of FDA As Well As Investors * Stemline Therapeutics (STML) Gets One Step Closer to EMA Approval; Analyst Weighs in With U.S. Angle * Here Are My Top 3 Biotech Stocks